Epinephrine
- Generic Name
- Epinephrine
- Brand Names
- Adrenalin, Allerject, Anapen, Articadent, Astracaine, Auvi-Q, Citanest, Citanest Forte, Emerade, Epipen, Lignospan, Marcaine, Marcaine With Epinephrine, Octocaine, Octocaine With Epinephrine, Orabloc, Scandonest, Sensorcaine, Sensorcaine With Epinephrine, Septanest, Septocaine, Symjepi, Ultacan, Ultracaine, Vivacaine, Xylocaine, Xylocaine With Epinephrine, Zorcaine, Eurneffy
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13NO3
- CAS Number
- 51-43-4
- Unique Ingredient Identifier
- YKH834O4BH
- Background
Epinephrine, also known as adrenaline, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new produ...
- Indication
Epinephrine injection is indicated in the emergency treatment of type I allergic reactions, including anaphylaxis. It is also used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
...
- Associated Conditions
- Anaphylaxis, Angioneurotic Edema, Bleeding, Bronchospasm, Complete Heart Block, Hypotension, Idiopathic Anaphylaxis, Laryngotracheobronchitis, Mild Intermittent Asthma, Nasal Congestion, Open Angle Glaucoma (OAG), Respiratory Distress, Severe Asthma, Syncope, Type I Hypersensitivity, Urticaria, Uterine Contractions, Ventricular Fibrillation, Resuscitation in cardiac arrest following anesthetic accidents, Severe hypersensitivity reactions, Unresponsive Asystole, Unresponsive Bradycardia
- Associated Therapies
- -
Sublingual epinephrine film moving forward, NDA anticipated by early next year
Aquestive Therapeutics plans to submit an NDA for its Anaphylm sublingual epinephrine film in Q1 2025, aiming for a launch in late 2025 or early 2026, pending FDA approval. The film aims to provide a non-invasive, oral alternative to traditional epinephrine delivery methods for anaphylaxis treatment.
Pharmacovigilance Industry Analysis Report 2024-2030: Biotechnology Companies
The global pharmacovigilance market is expected to reach USD 11.78 billion by 2030, growing at a CAGR of 6.8% due to increasing Adverse Drug Reactions (ADR). Key drivers include ADR-related hospitalizations and the role of PV services in clinical trials. Technological advancements and outsourcing trends are boosting market growth, with biotechnology companies focusing on R&D for novel products.
Pharmacovigilance Industry Analysis Report 2024-2030:
The global pharmacovigilance market is expected to reach USD 11.78 billion by 2030, growing at a CAGR of 6.8% due to increasing ADR incidents. Key drivers include technological advancements in PV software, outsourcing trends, and regulatory pressures. Biotechnology companies are projected to have the fastest growth, focusing on R&D for novel products. North America leads in market share, while collaborations and acquisitions are strategic moves by industry players.
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001
IN-001, a liquid epinephrine sublingual spray, showed rapid absorption (100 pg/mL in 9 min) and sustained PK (above 100 pg/mL for 2 hrs), outperforming existing products. It’s safe, with mild AEs, and resistant to extreme temperatures, positioning it as a reliable, needle-free anaphylaxis treatment.
Hand cooling induces changes in the kinetics of oxygen uptake
Article references on exercise physiology, focusing on parameters of ventilatory and gas exchange dynamics, O2 uptake response kinetics, muscle metabolism, and hormonal responses to exercise.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath